Cited by 3,634PARP inhibition in cancer therapyBRCA gene mutations in cancerAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Open access

Fong, Peter C., Boss, David S., Yap, Timothy A., Tutt, Andrew, Wu, Peijun, Mergui-Roelvink, Marja, Mortimer, Peter, Swaisland, Helen, Lau, Alan, O'Connor, Mark J., Ashworth, Alan, Carmichael, James, Kaye, Stan B., Schellens, Jan H.M., de Bono, Johann S.·2009·New England Journal of Medicine

DOI 10.1056/nejmoa0900212

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repair defects, including those arising in carriers of a BRCA1 or BRCA2 mutation. We conducted a clinical evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor. METHODS: This was a phase 1 trial that included the analysis of pharmacokinetic and pharmacodynamic characteristics of olaparib. Selection was aimed at having a study population enriched in carriers of a BRCA1 or BRCA2 mutation. RESULTS: We enrolled and treated 60 patients; 22 were carriers of a BRCA1 or BRCA2 mutation and 1 had a strong family history of BRCA-associated cancer but declined to undergo mutational testing. The olaparib dose and schedule were increased from 10 mg daily for 2 of every 3 weeks to 600 mg twice daily continuously. Reversible dose-limiting toxicity was seen in one of eight patients receiving 400 mg twice daily (grade 3 mood alteration and fatigue) and two of five patients receiving 600 mg twice daily (grade 4 thrombocytopenia and grade 3 somnolence). This led us to enroll another cohort, consisting only of carriers of a BRCA1 or BRCA2 mutation, to receive olaparib at a dose of 200 mg twice daily. Other adverse effects included mild gastrointestinal symptoms. There was no obvious increase in adverse effects seen in the mutation carriers. Pharmacokinetic data indicated rapid absorption and elimination; pharmacodynamic studies confirmed PARP inhibition in surrogate samples (of peripheral-blood mononuclear cells and plucked eyebrow-hair follicles) and tumor tissue. Objective antitumor activity was reported only in mutation carriers, all of whom had ovarian, breast, or prostate cancer and had received multiple treatment regimens. CONCLUSIONS: Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation. (ClinicalTrials.gov number, NCT00516373.)

Integrity signals

Registry

Crossref · 10.1056/nejmoa0900212

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Self-citation
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,690
Self-citation
The PARP superfamily
Amé, J., Spenlehauer, C., & de MURCIA, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,463
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1691 · Cited by 1,405
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O’Connor, M. J., Tutt, A. N. J., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,311
Self-citation
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086

Flagged first, then by citations

Show all 30 references

Research works printed but not linked: 1

10.1042/BST0290655 · DOI

Sorted by citations

Items 701–800 of 1,012

Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer
Ding, Y., Li, N., Dong, B., Guo, W., Wei, H., Chen, Q., Yuan, H., Han, Y., Chang, H., Kan, S., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci123557 · Cited by 93
Self-citation
BRCA2 and Other DDR Genes in Prostate Cancer
Nombela, P., Lozano, R., Aytés, À., Mateo, J., Olmos, D., & Castro, E. (2019) · Cancers · doi:10.3390/cancers11030352 · Cited by 93
Therapeutic Targeting of DNA Damage Response in Cancer
Choi, W., & Lee, E. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031701 · Cited by 97
BET proteins: Biological functions and therapeutic interventions
Guo, J., Zheng, Q., & Peng, Y. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108354 · Cited by 96
Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness
Lips, E. H., Laddach, N., Savola, S. P., Vollebergh, M. A., Oonk, A. M. M., Imholz, A. L. T., Wessels, L. F. A., Wesseling, J., Nederlof, P. M., & Rodenhuis, S. (2011) · Breast Cancer Research · doi:10.1186/bcr3049 · Cited by 91
BRCAness: Finding the Achilles Heel in Ovarian Cancer
Rigakos, G., & Razis, E. D. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0028 · Cited by 93
Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer
Garsed, D. W., Alsop, K., Fereday, S., Emmanuel, C., Kennedy, C. J., Etemadmoghadam, D., Gao, B., Gebski, V., Garès, V., Christie, E. L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1621 · Cited by 91
Deubiquitylating Enzymes and DNA Damage Response Pathways
Jacq, X., Kemp, M. I., Martin, N. M. B., & Jackson, S. P. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9635-3 · Cited by 90
Defective homologous recombination DNA repair as therapeutic target in advanced chordoma
Gröschel, S., Hübschmann, D., Raimondi, F., Horak, P., Warsow, G., Fröhlich, M., Klink, B., Gieldon, L., Hutter, B., Kleinheinz, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09633-9 · Cited by 92
Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
Jannetti, S. A., Zeglis, B. M., Zalutsky, M. R., & Reiner, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00170 · Cited by 91
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy
Javle, M. M., & Curtin, N. J. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011417039 · Cited by 94
Triple-Negative Breast Cancers: Unique Clinical Presentations and Outcomes
Billar, J. A. Y., Dueck, A. C., Stucky, C.-C., Gray, R. J., Wasif, N., Northfelt, D., McCullough, A. E., & Pockaj, B. A. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1260-4 · Cited by 90
Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target
Plummer, R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0984 · Cited by 90
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery
Bundred, N., Gardovskis, J., Jaskiewicz, J., Eglitis, J., Paramonov, V., McCormack, P., Swaisland, H., Cavallin, M., Parry, T., Carmichael, J., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9922-7 · Cited by 89
Self-citation
Poly ( ADP ) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
Owonikoko, T. K., Zhang, G., Deng, X., Rossi, M. R., Switchenko, J. M., Doho, G., Chen, Z., Kim, S., Strychor, S., Christner, S. M., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.317 · Cited by 89
Standardized decision support in next generation sequencing reports of somatic cancer variants
Dienstmann, R., Dong, F., Borger, D. R., Dias-Santagata, D. C., Ellisen, L. W., Le, L. P., & Iafrate, A. J. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.03.021 · Cited by 90
Translational research in oncology—10 years of progress and future prospects
Doroshow, J. H., & Kummar, S. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.158 · Cited by 91
Review: Practical considerations in ovarian cancer chemotherapy
Cristea, M. C., Han, E. S., Salmon, L., & Morgan, R. J. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010361333 · Cited by 89
Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy
Xu, Y., Diao, L., Chen, Y., Liu, Y., Wang, C. Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt011 · Cited by 89
Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer
Chen, Y., & Zhang, Y. (2018) · Advanced Science · doi:10.1002/advs.201700964 · Cited by 91
Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy
Chang, X., Sun, D., Shi, D., Wang, G., Chen, Y., Zhang, K., Tan, H., Liu, J., Liu, B., & Ouyang, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.06.003 · Cited by 89
Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features
Venkitaraman, R. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.189 · Cited by 89
Molecular insights on basal-like breast cancer
Valentin, M. D., da Silva, S. D., Privat, M., Alaoui‐Jamali, M. A., & Bignon, Y. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1934-z · Cited by 89
The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy
Nowsheen, S., Bonner, J. A., & Yang, E. S.-H. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.084 · Cited by 91
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Gelmon, K. A. (2011) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2011.03.043 · Cited by 89
Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future
Fields, E. C., McGuire, W. P., Lin, L. L., & Temkin, S. M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00177 · Cited by 89
PARP inhibitors for anticancer therapy
Curtin, N. J. (2014) · Biochemical Society Transactions · doi:10.1042/bst20130187 · Cited by 89
A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy
Liu, C., Srihari, S., Cao, K. L., Chenevix‐Trench, G., Simpson, P. T., Ragan, M. A., & Khanna, K. K. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku284 · Cited by 91
Resistance to DNA repair inhibitors in cancer
Baxter, J. S., Zatreanu, D. A., Pettitt, S. J., & Lord, C. J. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13224 · Cited by 91
Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype
Gourley, C., Michie, C. O., Roxburgh, P., Yap, T. A., Harden, S., Paul, J., Ragupathy, K., Todd, R., Petty, R., Reed, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1082 · Cited by 88
Self-citation
PARP Inhibitors as P-glyoprotein Substrates
Lawlor, D., Martin, P., Busschots, S., Thery, J., O’Leary, J. J., Hennessy, B. T., & Stordal, B. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23952 · Cited by 88
BRCA1 loss activates cathepsin L–mediated degradation of 53BP1 in breast cancer cells
Grotsky, D. A., González-Suárez, I., Novell, A., Neumann, M. A., Yaddanapudi, S. C., Croke, M., Martínez‐Alonso, M., Redwood, A. B., Ortega‐Martínez, S., Feng, Z., et al. (2013) · The Journal of Cell Biology · doi:10.1083/jcb.201204053 · Cited by 89
HPF1 remodels the active site of PARP1 to enable the serine ADP-ribosylation of histones
Sun, F.-H., Zhao, P., Zhang, N., Kong, L., Wong, C. C. L., & Yun, C. (2021) · Nature Communications · doi:10.1038/s41467-021-21302-4 · Cited by 90
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
Tattersall, A., Ryan, N. A. J., Wiggans, A. J., Rogozińska, E., & Morrison, J. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007929.pub4 · Cited by 89
Improved survival for BRCA2‐associated serous ovarian cancer compared with both BRCA‐negative and BRCA1‐associated serous ovarian cancer
Hyman, D. M., Zhou, Q. C., Iasonos, A. E., Grisham, R. N., Arnold, A. G., Phillips, M. F., Bhatia, J., Levine, D. A., Aghajanian, C. A., Offit, K., et al. (2011) · Cancer · doi:10.1002/cncr.26655 · Cited by 87
Cancer treatment according to BRCA1 and BRCA2 mutations
Maxwell, K. N., & Domchek, S. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.123 · Cited by 89
PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications
Drew, Y., & Plummer, R. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.10.001 · Cited by 88
DNA Repair Targeting and Radiotherapy: A Focus on the Therapeutic Ratio
Thoms, J., & Bristow, R. G. (2010) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2010.06.003 · Cited by 92
New Therapeutic and Biomarker Discovery for Peripheral Diabetic Neuropathy: PARP Inhibitor, Nitrotyrosine, and Tumor Necrosis Factor-α
Drel, V. R., Lupachyk, S., Shevalye, H., Vareniuk, І., Xu, W., Zhang, J., Delamere, N. A., Shahidullah, M., Slusher, B. S., & Obrosova, I. G. (2010) · Endocrinology · doi:10.1210/en.2009-1342 · Cited by 86
ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective
Saxena, R., & Dwivedi, A. (2010) · Medicinal Research Reviews · doi:10.1002/med.20209 · Cited by 88
LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL
Parvin, S., Ramírez-Labrada, A., Aumann, S., Lu, X., Weich, N., Santiago, G. E., Cortizas, E. M., Sharabi, E., Zhang, Y., Sánchez-Garcı́a, I., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.07.007 · Cited by 88
Hereditary breast cancer: syndromes, tumour pathology and molecular testing
Sokolova, A., Johnstone, K. J., Reed, A. E. M., Simpson, P. T., & Lakhani, S. R. (2022) · Histopathology · doi:10.1111/his.14808 · Cited by 95
The Future of Precision Oncology
Rulten, S. L., Grose, R. P., Gatz, S. A., Jones, J. L., & Cameron, A. J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612613 · Cited by 92
The role of PARP1 in the DNA damage response and its application in tumor therapy
Wang, Z., Wang, F., Tang, T.-S., & Guo, C. (2012) · Frontiers of Medicine · doi:10.1007/s11684-012-0197-3 · Cited by 87
Achievements and unmet needs in the management of advanced ovarian cancer
Guarneri, V., Piacentini, F., Barbieri, E., & Conte, P. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.11.033 · Cited by 85
The PARP Inhibitors, Veliparib and Olaparib, Are Effective Chemopreventive Agents for Delaying Mammary Tumor Development in BRCA1-deficient Mice
To, C., Kim, E., Royce, D. B., Williams, C. R., Collins, R. M., Risingsong, R., Sporn, M. B., & Liby, K. T. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0047 · Cited by 86
The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer
Mauri, G., Arena, S., Siena, S., Bardelli, A., & Bianchi, A. S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.027 · Cited by 87
Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study
Groenland, S. L., van Eerden, R. A. G., Westerdijk, K., Meertens, M., Koolen, S. L. W., Moes, D. J. A. R., de Vries, N., Rosing, H., Otten, H.-M. M. B., Vulink, A. J. E., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.010 · Cited by 85
Signal transduction therapy of cancer
Levitzki, A., & Klein, S. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.04.001 · Cited by 86
Having Pancreatic Cancer with Tumoral Loss of ATM and Normal TP53 Protein Expression Is Associated with a Poorer Prognosis
Kim, H., Saka, B., Knight, S., Borges, M. W., Childs, E. J., Klein, A. P., Wolfgang, C. L., Herman, J. M., Adsay, V. N., Hruban, R. H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1239 · Cited by 88
Crystal Structure of the Catalytic Domain of Human PARP2 in Complex with PARP Inhibitor ABT-888
Karlberg, T., Hammarström, M., Schutz, P., Svensson, L., & Schuler, H. (2010) · Biochemistry · doi:10.1021/bi902079y · Cited by 85
RETRACTED: Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage
Lee, H., Yoon, C., Schmidt, B. H., Park, D. J., Zhang, A. Y., Erkizan, H. V., Toretsky, J. A., Kirsch, D. G., & Yoon, S. S. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0338 · Cited by 85
Retracted
Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells
Hu, K., Law, J. H., Fotovati, A., & Dunn, S. E. (2012) · Breast Cancer Research · doi:10.1186/bcr3107 · Cited by 86
Cytoplasmic Poly(Adenosine Diphosphate–Ribose) Polymerase Expression Is Predictive and Prognostic in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy
von Minckwitz, G., Müller, B. M., Loibl, S., Budczies, J., Hanusch, C. A., Darb‐Esfahani, S., Hilfrich, J., Weiss, E., Huober, J., Blohmer, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.9079 · Cited by 85
E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling
McGonigle, S., Chen, Z., Wu, J., Chang, P., Kolber, D. L., Ackermann, K. E., Twine, N. C., Shie, J., Miu, J. T., Huang, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5846 · Cited by 88
Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study
Lenglet, A., Liabeuf, S., Esper, N. E., Brisset, S., Mansour, J., Lemaire‐Hurtel, A., Mary, A., Brazier, M., Kamel, S., Mentaverri, R., et al. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw042 · Cited by 85
Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan
Zander, S. A. L., Kersbergen, A. J., van der Burg, E., de Water, N., van Tellingen, O., Gunnarsdottir, S., Jaspers, J. E., Pajic, M., Nygren, A. O. H., Jonkers, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3367 · Cited by 84
Towards systematic functional characterization of cancer genomes
Boehm, J. S., & Hahn, W. C. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3013 · Cited by 84
BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis
Zhu, Y., Wu, J., Zhang, C., Sun, S., Zhang, J., Liu, W., Huang, J., & Zhang, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.12158 · Cited by 92
Profiles of Radioresistance Mechanisms in Prostate Cancer
Chaiswing, L., Weiss, H. L., Jayswal, R. D., Clair, D. K. S., & Kyprianou, N. (2018) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2018025946 · Cited by 87
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
Emens, L. A., Adams, S., Cimino‐Mathews, A., Disis, M. L., Gatti-Mays, M. E., Ho, A. Y., Kalinsky, K. M., McArthur, H. L., Mittendorf, E. A., Nanda, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002597 · Cited by 84
Mainstreaming genetic testing of cancer predisposition genes
Rahman, N. (2014) · Clinical Medicine · doi:10.7861/clinmedicine.14-4-436 · Cited by 84
New Insights into PARP Inhibitors' Effect on Cell Cycle and Homology-Directed DNA Damage Repair
Jelinic, P., & Levine, D. A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0906-t · Cited by 85
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma
Gill, S. J., Travers, J., Pshenichnaya, I., Kogera, F., Barthorpe, S., Mironenko, T., Richardson, L., Benes, C. H., Stratton, M. R., McDermott, U., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140988 · Cited by 83
How to kill tumor cells with inhibitors of poly(ADP‐ribosyl)ation
Mangerich, A., & Bürkle, A. (2010) · International Journal of Cancer · doi:10.1002/ijc.25683 · Cited by 85
Optimal treatment for relapsing ovarian cancer
Ledermann, J. A., & Kristeleit, R. S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq377 · Cited by 83
Targeting Tumor Suppressor Networks for Cancer Therapeutics
Guo, X. E., Ngo, B., Modrek, A. S., & Lee, W. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106095151 · Cited by 89
DNA double-strand break signaling and human disorders
Bohgaki, T., Bohgaki, M., & Hakem, R. (2010) · Genome Integrity · doi:10.1186/2041-9414-1-15 · Cited by 95
The challenge of intratumour heterogeneity in precision medicine
Seoane, J., & Mattos‐Arruda, L. D. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12240 · Cited by 85
Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma
Brohl, A. S., Patidar, R., Turner, C., Wen, X., Song, Y., Wei, J. S., Calzone, K. A., & Khan, J. I. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.206 · Cited by 83
Practical Approach to Triple-Negative Breast Cancer
Gadi, V. K., & Davidson, N. E. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.022632 · Cited by 82
Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches
Guidugli, L., Shimelis, H., Masica, D. L., Pankratz, V. S., Lipton, G. B., Singh, N., Hu, C., Monteiro, Á. N. A., Lindor, N. M., Goldgar, D. E., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.12.013 · Cited by 82
Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies
Zhu, Y., Liu, J., Park, J., Rai, P., & Zhai, R. G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.002 · Cited by 82
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
Yang, X.-D., Kong, F.-E., Qi, L., Lin, J., Yan, Q., Loong, J. H. C., Xi, S., Zhao, Y., Zhang, Y., Yuan, Y., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01315-9 · Cited by 82
Mechanism of PARP inhibitor resistance and potential overcoming strategies
Fu, X., Li, P., Zhou, Q., He, R., Wang, G., Zhu, S., Bagheri, A., Kupfer, G. M., Pei, H., & Li, J. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.014 · Cited by 89
PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: Correlation with peripheral nerve function
Lupachyk, S., Shevalye, H., Maksimchyk, Y., Drel, V. R., & Obrosova, I. G. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.01.037 · Cited by 82
Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition
Horton, J. K., Stefanick, D. F., Prasad, R., Gassman, N. R., Kedar, P. S., & Wilson, S. H. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0502 · Cited by 83
Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy
Lips, E. H., Mulder, L., Hannemann, J., Laddach, N., Peeters, M.-J. T. F. D. V., van de Vijver, M. J., Wesseling, J., Nederlof, P. M., & Rodenhuis, S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq468 · Cited by 81
Genomic instability and the selection of treatments for cancer
Martin, S. A., Hewish, M., Lord, C. J., & Ashworth, A. (2009) · The Journal of Pathology · doi:10.1002/path.2631 · Cited by 80
Self-citation
Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions
Alkema, N. G., Wisman, G. B. A., van der Zee, A. G. J., van Vugt, M. A. T. M., & de Jong, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.005 · Cited by 84
Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer
Leichman, L., Groshen, S. G., O’Neil, B. H., Messersmith, W. A., Berlin, J. D., Chan, E. W., Leichman, C. G., Cohen, S. J., Cohen, D. J., Lenz, H., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0319 · Cited by 82
Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis
Jiang, T., Shi, W., Wali, V. B., Pongor, L. S., Li, C., Lau, R., Győrffy, B., Lifton, R. P., Symmans, W. F., Pusztai, L., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002193 · Cited by 84
Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer
Liu, T., Song, S., Wang, X., & Hao, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112954 · Cited by 81
The inherited genetics of ovarian and endometrial cancer
Gayther, S. A., & Pharoah, P. D. P. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.03.001 · Cited by 80
Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy
Nitta, M., Kozono, D., Kennedy, R. D., Stommel, J. M., Ng, K., Zinn, P. O., Kushwaha, D. S., Kesari, S., Furnari, F. B., Hoadley, K. A., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010767 · Cited by 81
PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
Boussios, S., Karathanasi, A., Cooke, D., Neille, C., Sadauskaite, A., Moschetta, M., Zakynthinakis-Kyriakou, N., & Pavlidis, N. A. (2019) · Diagnostics · doi:10.3390/diagnostics9020055 · Cited by 80
ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer
Wang, J., Zhang, C., Chen, K., Tang, H., Tang, J., Song, C., & Xie, X. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3467-3 · Cited by 80
DNA repair signature is associated with anthracycline response in triple negative breast cancer patients
Rodriguez, A. A., Makris, A., Wu, M.-F., Rimawi, M. F., Froehlich, A. M., Dave, B., Hilsenbeck, S. G., Chamness, G. C., Lewis, M. T., Dobrolecki, L. E., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0983-z · Cited by 79
Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers
Chen, K., Zhang, J., Beeraka, N. M., Tang, C., Babayeva, Y. V., Sinelnikov, M. Y., Zhang, X., Zhang, J., Liu, J., Reshetov, I. V., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.820968 · Cited by 81
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
Carden, C. P., Sarker, D., Postel-Vinay, S. C., Yap, T. A., Attard, G., Banerji, U., Garrett, M. D., THOMAS, G. V., Workman, P., Kaye, S. B., et al. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.11.006 · Cited by 81
Self-citation
Regulators of homologous recombination repair as novel targets for cancer treatment
Krajewska, M., Fehrmann, R. S. N., de Vries, E. G. E., & van Vugt, M. A. T. M. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00096 · Cited by 81
Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review
Jong, M. A.-D., de Bock, G. H., van Asperen, C. J., Mourits, M. J. E., de Hullu, J. A., & Kets, C. M. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.009 · Cited by 79
Profile of veliparib and its potential in the treatment of solid tumors
Wagner, L. M. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s69935 · Cited by 80
High‐Yielding, Two‐Step 18F Labeling Strategy for 18F‐PARP1 Inhibitors
Keliher, E. J., Reiner, T., Turetsky, A., Hilderbrand, S. A., & Weissleder, R. (2011) · ChemMedChem · doi:10.1002/cmdc.201000426 · Cited by 78
The Importance of Biopsy in the Era of Molecular Medicine
Ziv, E., Durack, J. C., & Solomon, S. B. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000228 · Cited by 80
The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy–Current progress and future direction
Zhao, Y., Zhang, L., Jiang, T., Long, J., Ma, Z.-Y., Lü, A., Cheng, Y., & Cao, D. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112570 · Cited by 78
Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
Singh, D. D., Parveen, A., & Yadav, D. K. (2021) · Biomedicines · doi:10.3390/biomedicines9111512 · Cited by 83
Cytoplasmic PARP1 links the genome instability to the inhibition of antiviral immunity through PARylating cGAS
Wang, F., Zhao, M., Chang, B., Zhou, Y., Wu, X., Ma, M., Liu, S., Cao, Y., Zheng, M., Dang, Y., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.03.034 · Cited by 79
Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors
Norris, R. E., Adamson, P. C., Nguyen, V. T., & Fox, E. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24697 · Cited by 78
Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers
Lee, L. J., Alexander, B. M., Schnitt, S. J., Comander, A. H., Gallagher, B. M., Garber, J. E., & Tung, N. (2011) · Cancer · doi:10.1002/cncr.25911 · Cited by 78

Authors: Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., Ashworth, A., Carmichael, J., Kaye, S. B., Schellens, J. H. M., & de Bono, J. S.
Affiliations: National Health Service (GB)
The Netherlands Cancer Institute (NL)
Institute of Cancer Research (GB)
AstraZeneca (United Kingdom) (GB)
Utrecht University (NL)
ORCID: Fong, Peter C.
Yap, Timothy A.
Tutt, Andrew
Wu, Peijun
Mortimer, Peter
Lau, Alan
Ashworth, Alan
Kaye, Stan B.
Schellens, Jan H.M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2009-07-09
Volume: 361
Issue: 2
Pages: 123-134
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa0900212
OpenAlex: W2171972386
Cited by: 3,634
References: 30
Citations by year: 2026: 79 · 2025: 113 · 2024: 126 · 2023: 152 · 2022: 188 · 2021: 189 · 2020: 173 · 2019: 195 · 2018: 190 · 2017: 214 · 2016: 249 · 2015: 252 · 2014: 244 · 2013: 247 · 2012: 285
FWCI: 170.91
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Research Portal (King's College London) (submittedVersion)
Funders: AstraZeneca
Royal Marsden NHS Foundation Trust
NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
Cancer Research UK (A8363)
National Institute for Health and Care Research
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: olaparib, PARP inhibitors, BRCA1 mutation carriers, BRCA2 mutation carriers, synthetic lethality, DNA repair deficiency, ovarian cancer, breast cancer, prostate cancer, pharmacokinetics, pharmacodynamics, dose-limiting toxicity, thrombocytopenia, anticancer activity
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Female, Heterozygote, Humans, Male, Middle Aged, Neoplasms, Phthalazines, Piperazines, Drug Design, Germ-Line Mutation, Genes, BRCA1, Genes, BRCA2, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks